These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36696068)

  • 1. Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients.
    Weng C; Xie R; Han G; Yuan Y; Li S; Wang C; Wang X; Jiang W; Jiang L
    Infect Dis Ther; 2023 Feb; 12(2):649-662. PubMed ID: 36696068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.
    Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China.
    Li P; Huang L; Han R; Tang M; Fei G; Zeng D; Wang R
    Expert Rev Anti Infect Ther; 2024 Jun; 22(6):469-477. PubMed ID: 38300126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of
    Feng Y; Liu Y; Liu L; Liu Y; Jiang Y; Hou Y; Zhou Y; Song R; Chen X; Wang X
    Front Pharmacol; 2022; 13():978979. PubMed ID: 36052136
    [No Abstract]   [Full Text] [Related]  

  • 6. The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial.
    Zhong W; Jiang X; Yang X; Feng T; Duan Z; Wang W; Sun Z; Chen L; Nie X; Zhu C; Zhang W; Li Y
    Front Med (Lausanne); 2022; 9():980002. PubMed ID: 36148451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
    Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
    Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China.
    Yang W; Peng Y; Wang C; Cai H; Zhang L; Xu J; Wang Y; Wang M; Zhao M; Yu K
    Infect Drug Resist; 2024; 17():1267-1279. PubMed ID: 38572421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report.
    Zhang L; Zhang S; Han J; Yi Y; Zhou H; Li J
    Medicine (Baltimore); 2022 Nov; 101(45):e31361. PubMed ID: 36397388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study.
    Qiu Y; Wen H; Wang H; Sun W; Li G; Li S; Wang Y; Zhai J; Zhan Y; Su Y; Long Z; Li Z; Ye F
    Front Pharmacol; 2024; 15():1401658. PubMed ID: 39224781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022.
    Kim JM; Yoo MG; Bae SJ; Kim J; Lee H
    J Korean Med Sci; 2023 Jul; 38(27):e211. PubMed ID: 37431541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.
    Hao X; Bao Z; Dai R; Wu X; Li X; Zhang M; Li H; Xu L; Qiao P; Liu X; Hu W; Zhang Z; Fang J; Zhou M; Wang W; Qu J
    Front Med; 2024 Feb; 18(1):169-179. PubMed ID: 37978164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study.
    Liu J; Pan X; Zhang S; Li M; Ma K; Fan C; Lv Y; Guan X; Yang Y; Ye X; Deng X; Wang Y; Qin L; Xia Z; Ge Z; Zhou Q; Zhang X; Ling Y; Qi T; Wen Z; Huang S; Zhang L; Wang T; Liu Y; Huang Y; Li W; Du H; Chen Y; Xu Y; Zhao Q; Zhao R; Annane D; Qu J; Chen D
    Lancet Reg Health West Pac; 2023 Apr; 33():100694. PubMed ID: 36777445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS-COV-2 infection: A systematic review.
    Zhu CT; Yin JY; Chen XH; Liu M; Yang SG
    Rev Med Virol; 2023 Nov; 33(6):e2476. PubMed ID: 37578892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study.
    Yan G; Zhou J; Zhu H; Chen Y; Lu Y; Zhang T; Yu H; Wang L; Xu H; Wang Z; Zhou W
    Ann Transl Med; 2022 Jun; 10(11):619. PubMed ID: 35813342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study.
    Deng X; Jiang Y; Chen W; Qin X; Chen J; Li H; Cao Q
    Transl Cancer Res; 2024 Aug; 13(8):4219-4230. PubMed ID: 39262461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.